Revenue: The sum of all revenue fields included for a company's operating activities.
Theravance Biopharma, Inc. (TBPH) had Revenue of $45.89M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
|
Revenue |
$45.89M |
$61.02M |
|
-- |
|
$45.89M |
|
$25.88M |
|
$20.01M |
|
$53.06M |
|
$73.07M |
|
$73.07M |
|
$61.02M |
|
$61.02M |
|
$61.02M |
|
$66.30M |
|
$20.01M |
|
$19.10M |
|
50.32M |
|
51.51M |
|
$1.21 |
|
$1.18 |
|
| Balance Sheet Financials | |
$418.46M |
|
$5.89M |
|
$67.11M |
|
$485.57M |
|
$38.30M |
|
-- |
|
$150.54M |
|
$188.85M |
|
$296.72M |
|
$296.72M |
|
$296.72M |
|
51.07M |
|
| Cash Flow Statement Financials | |
$238.54M |
|
$-105.28M |
|
$-3.25M |
|
$38.63M |
|
$168.64M |
|
$130.01M |
|
$18.48M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
43.61% |
|
43.61% |
|
-- |
|
159.22% |
|
132.98% |
|
$238.50M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
-- |
|
0.48 |
|
187.37 |
|
20.57% |
|
20.57% |
|
12.57% |
|
20.57% |
|
$5.81 |
|
$4.63 |
|
$4.63 |
|